Axenis

Paris, France Founded: 2010 • Age: 16 yrs Acquired By GenOway
Chimeric in-vivo mouse models for biomedical research are developed.
Annual revenue - Latest available
Total funding - 2 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Axenis

Axenis is a company based in Paris (France) founded in 2010 was acquired by GenOway in September 2018. Axenis operates in a competitive market with competitors including Biocytogen, Interius Biotherapeutics, Applied StemCell, GenOway and Nagi Bioscience, among others.

  • Headquarter Paris, France
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    GenOway

    (Sep 04, 2018)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Axenis

Investors in Axenis

Axenis has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Commission, GenOway and EIC Fund.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Locked Locked Locked
Institution of the European Union responsible for upholding the EU treaties
Locked Locked Locked
Provider of transgenic rodent models and customized cell lines for preclinical development
Locked Locked Locked
Premium access

Investor details for Axenis

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Axenis

Investments
Premium access

Investment portfolio details for Axenis

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Axenis

Premium access

Detailed financials for Axenis

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Axenis Comparisons

Axenis Primary company
Description
Chimeric in-vivo mouse models for biomedical research are de...
Location
Paris, France
Founded Year
2010
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Axenis

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Axenis

Axenis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biocytogen, Interius Biotherapeutics, Applied StemCell, GenOway and Nagi Bioscience, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Integrated solutions for next-generation antibody drug development are provided.
Locked Locked Locked
Developer of gene therapies for treating multiple diseases
Locked Locked Locked
Provider of animal and cell line models as tools for drug discovery and diagnostics
Locked Locked Locked
Provider of transgenic rodent models and customized cell lines for preclinical development
Locked Locked Locked
Developer of a organism on a chip based technology
Locked Locked Locked
Humanized models and drug screening technologies are developed for research.
Premium access

Detailed competitors of Axenis

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Axenis

Premium access

Complete news archive for Axenis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Axenis

Axenis was founded in 2010 and raised its 1st funding round 5 years after it was founded.

Axenis is headquartered in Paris, France.

Axenis was founded in 2010 in Paris, France, within the biotechnology sector. Immunocompromised mice, lacking T-cells, B-cells, and NK cells through Rag2-- and IL-2R-- modifications, are grafted with human blood cells to create the BRGS HIS model. This humanized immune system is applied in studies of immunology, inflammation, infectious diseases, vaccine and drug screening, oncology, stem cell transplantation, gene therapy, and personalized medicine.

Axenis's top competitors include Biocytogen, Applied StemCell and GenOway.

Axenis has 3 investors. Key investors include European Commission, GenOway, and EIC Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available